164 related articles for article (PubMed ID: 12478110)
21. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
22. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20.
Wu X; Kakehi Y; Zeng Y; Taoka R; Tsunemori H; Inui M
J Urol; 2005 Dec; 174(6):2138-42, discussion 2142-3. PubMed ID: 16280744
[TBL] [Abstract][Full Text] [Related]
23. Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.
Salomo K; Huebner D; Boehme MU; Herr A; Brabetz W; Heberling U; Hakenberg OW; Jahn D; Grimm MO; Steinbach D; Horstmann M; Froehner M; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1757-1769. PubMed ID: 28484844
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of bladder cancer using telomerase activity in voided urine.
Cheng CW; Chueh SC; Chern HD
J Formos Med Assoc; 2000 Dec; 99(12):920-5. PubMed ID: 11155745
[TBL] [Abstract][Full Text] [Related]
26. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
[TBL] [Abstract][Full Text] [Related]
27. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder.
Melissourgos ND; Kastrinakis NG; Skolarikos A; Pappa M; Vassilakis G; Gorgoulis VG; Salla C
Urology; 2005 Sep; 66(3):536-41. PubMed ID: 16140073
[TBL] [Abstract][Full Text] [Related]
28. Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients.
Morsi MI; Youssef AI; Hassouna ME; El-Sedafi AS; Ghazal AA; Zaher ER
J Egypt Natl Canc Inst; 2006 Mar; 18(1):82-92. PubMed ID: 17237854
[TBL] [Abstract][Full Text] [Related]
29. [Expression of antimicrobial peptide MUC7 in kidneys with pyelonephritis].
Lehmann J; Suttmann H; Gerber M; Shayesteh-Kheslat R; Hartmann J; Hack M; Siemer S; Stöckle M
Urologe A; 2006 Oct; 45(10):1300, 1302-7. PubMed ID: 16770570
[TBL] [Abstract][Full Text] [Related]
30. Urine detection of survivin and diagnosis of bladder cancer.
Smith SD; Wheeler MA; Plescia J; Colberg JW; Weiss RM; Altieri DC
JAMA; 2001 Jan; 285(3):324-8. PubMed ID: 11176843
[TBL] [Abstract][Full Text] [Related]
31. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma.
Güdemann CJ; Weitz J; Kienle P; Lacroix J; Wiesel MJ; Soder M; Benner A; Staehler G; Doeberitz MV
J Urol; 2000 Aug; 164(2):532-6. PubMed ID: 10893639
[TBL] [Abstract][Full Text] [Related]
32. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
Golijanin D; Sherman Y; Shapiro A; Pode D
Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
[TBL] [Abstract][Full Text] [Related]
33. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
[TBL] [Abstract][Full Text] [Related]
34. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
37. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
38. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
39. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
[TBL] [Abstract][Full Text] [Related]
40. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
